Condition
Decreased Vascular Flow
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT01450371CompletedPrimary
Interferential Electrical Stimulation and Vasodilatation in Healthy Individuals
NCT01663883Not ApplicableCompletedPrimary
Optic Nerve Head Autoregulation During Changes in Arterial Blood Pressure
NCT00859833Not ApplicableCompleted
Effects of Body Mass Index on the Hyperemic Response to Regadenoson
Showing all 3 trials